Recent advances in the treatment of central nervous system tumors

Update on Cancer Therapeutics

Volumn 3, Issue 1, 2008, Pages 49-79

  Liu, Raymond ^a   Chang, Susan M ^a   Prados, Michael ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Astrocytoma; Brain metastases; Low grade glioma; Lymphoma; Malignant glioma; Neoplastic meningitis; Oligodendroglioma; Primary central nervous system; Targeted therapy

Indexed keywords

2 (2 DIMETHYLAMINOETHYL) 9 METHOXY 5 NITROPYRAZOLO[3,4,5 KL]ACRIDINE; 6 O BENZYLGUANINE; BETA INTERFERON; BEVACIZUMAB; CARBOPLATIN; CARMUSTINE; CEDIRANIB; CELECOXIB; COPPER; DENDRITIC CELL VACCINE; ERLOTINIB; ETOPOSIDE; HYDROXYUREA; IMATINIB; IRINOTECAN; LOMUSTINE; MARIMASTAT; METHOTREXATE; NIMUSTINE; PENICILLAMINE; PROCARBAZINE; RETINOIC ACID; ROFECOXIB; TAMOXIFEN; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE; TIPIFARNIB; UNINDEXED DRUG; VINCRISTINE;

ANGIOGENESIS; ASTROCYTOMA; BONE MARROW TOXICITY; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; COLON CANCER; DRUG DELIVERY SYSTEM; GLIOBLASTOMA; HEMATOLOGIC DISEASE; HUMAN; LUNG CANCER; LUNG FIBROSIS; MENINX DISORDER; MULTIPLE CYCLE TREATMENT; OLIGODENDROGLIOMA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEPSIS; STEM CELL TRANSPLANTATION; TOXIC HEPATITIS;

EID: 40849141140     PISSN: 1872115X     EISSN: 1872115X     Source Type: Journal    
DOI: 10.1016/j.uct.2007.11.002     Document Type: Review

References (252)

1. CBTRUS: Statistical Report: Primary Brain Tumors in the United States 1998-2002. Hinsdale, IL; 2005-2006.
2. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med 352 10 (2005) 987-996
3. Vredenburgh J.J., Desjardins A., Herndon II J.E., Dowell J.M., Reardon D.A., Quinn J.A., et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13 4 (2007) 1253-1259
4. Keles G.E., and Berger M.S. Advances in neurosurgical technique in the current management of brain tumors. Semin Oncol 31 5 (2004) 659-665
5. Lamborn K.R., Chang S.M., and Prados M.D. Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro-Oncology 6 3 (2004) 227-235
6. Shaw E., Berkey B., Coons S.W., Brachman D., Buckner J., Steizer K.J., et al. Initial report of Radiation Therapy Oncology Group (RTOG) 9802: prospective studies in adult low-grade glioma (LGG). J Clin Oncol 24 18S (2006) 1500
7. Stummer W., Pichlmeier U., Meinel T., Wiestler O.D., Zanella F., and Reulen H.J. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7 5 (2006) 392-401
8. Buckner J.C., Ballman K.V., Michalak J.C., Burton G.V., Cascino T.L., Schomberg P.J., et al. Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials. J Clin Oncol 24 24 (2006 Aug 20) 3871-3879
9. Curran Jr. W.J., Scott C.B., Nelson J.S., Weinstein A.S., Phillips T.L., Murray K., et al. A randomized trial of accelerated hyperfractionated radiation therapy and bis-chloroethyl nitrosourea for malignant glioma. A preliminary report of Radiation Therapy Oncology Group 83-02. Cancer 70 12 (1992 Dec 15) 2909-2917
10. Werner-Wasik M., Scott C.B., Nelson D.F., Gaspar L.E., Murray K.J., Fischbach J.A., et al. Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83-02. Cancer 77 8 (1996) 1535-1543
11. Coughlin C., Scott C., Langer C., Coia L., Curran W., and Rubin P. Phase II, two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70. 4 Gy) based on tumor volume (>20 or < or = 20 cm(2), respectively) in the treatment of newly-diagnosed radiosurgery-ineligible glioblastoma multiforme patients. Int J Radiat Oncol Biol Phys 48 5 (2000 Dec 1) 1351-1358
12. Horiot J.C., van den Bogaert W., Ang K.K., Van der Schueren E., Bartelink H., Gonzalez D., et al. European Organization for Research on Treatment of Cancer trials using radiotherapy with multiple fractions per day. A 1978-1987 survey. Frontiers Radiat Ther Oncol 22 (1988) 149-161
13. Nomiya T., Kumabe T., Nemoto K., Takai Y., and Yamada S. Phase II study of high-dose hyperfractionated radiation therapy for grade 3 glioma. J Clin Oncol 23 16S (2005) 1559
14. Cardinale R., Won M., Choucair A., Gillin M., Chakravarti A., Schultz C., et al. A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023. Int J Radiat Oncol Biol Phys 65 5 (2006) 1422-1428
15. Wurm R.E., Kuczer D.A., Schlenger L., Matnjani G., Scheffler D., Cosgrove V.P., et al. Hypofractionated stereotactic radiotherapy combined with topotecan in recurrent malignant glioma. Int J Radiat Oncol Biol Phys 66 4 Suppl. (2006) S26-S32
16. Klautke G., Schutze M., Bombor I., Benecke R., Piek J., and Fietkau R. Concurrent chemoradiotherapy and adjuvant chemotherapy with Topotecan for patients with glioblastoma multiforme. J Neurooncol 77 2 (2006) 199-205
17. van den Bent M.J., Afra D., de Witte O., Ben Hassel M., Schraub S., Hoang-Xuan K., et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 366 9490 (2005 Sep 17-23) 985-990
18. Ogawa K., Yoshii Y., Inoue O., Toita T., Saito A., Kakinohana Y., et al. Phase II trial of radiotherapy after hyperbaric oxygenation with chemotherapy for high-grade gliomas. Br J Cancer 95 7 (2006) 862-868
19. Douglas J.G., Stelzer K.J., Mankoff D.A., Tralins K.S., Krohn K.A., Muzi M., et al. [F-18]-fluorodeoxyglucose positron emission tomography for targeting radiation dose escalation for patients with glioblastoma multiforme: clinical outcomes and patterns of failure. Int J Radiat Oncol Biol Phys 64 3 (2006) 886-891
20. Taphoorn M.J., Stupp R., Coens C., Osoba D., Kortmann R., van den Bent M.J., et al. Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol 6 12 (2005) 937-944
21. Athanassiou H., Synodinou M., Maragoudakis E., Paraskevaidis M., Verigos C., Misailidou D., et al. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol 23 10 (2005) 2372-2377
22. Hegi M.E., Diserens A.C., Gorlia T., Hamou M.F., de Tribolet N., Weller M., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. New Engl J Med 352 10 (2005) 997-1003
23. Brandes A.A., Tosoni A., Cavallo G., Bertorelle R., Gioia V., Franceschi E., et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br J Cancer 95 9 (2006) 1155-1160
24. Herrlinger U., Rieger J., Koch D., Loeser S., Blaschke B., Kortmann R.D., et al. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J Clin Oncol 24 27 (2006) 4412-4417
25. Mollemann M., Wolter M., Felsberg J., Collins V.P., and Reifenberger G. Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 113 3 (2005) 379-385
26. Levin N., Lavon I., Zelikovitsh B., Fuchs D., Bokstein F., Fellig Y., et al. Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer 106 8 (2006) 1759-1765
27. Rabik C.A., Njoku M.C., and Dolan M.E. Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy. Cancer Treat Rev 32 4 (2006) 261-276
28. Quinn JA, Vredenburgh J, Rich JN, Reardon DA, Desjardins A, Gururangan S, et al. Phase II trial of Gliadel plus O6-benzylguanine (O6-BG) for patients with recurrent glioblastoma multiforme. In: Abstract #1568, ASCO Annual Meeting. 2006.
29. Combs S.E., Gutwein S., Schulz-Ertner D., van Kampen M., Thilmann C., Edler L., et al. Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme. Phase I/II study. Strahlenther Onkol 181 6 (2005) 372-377
30. De Sanctis V., Mazzarella G., Osti M.F., Valeriani M., Alfo M., Salvati M., et al. Radiotherapy and sequential temozolomide compared with radiotherapy with concomitant and sequential temozolomide in the treatment of newly diagnosed glioblastoma multiforme. Anti-cancer Drugs 17 8 (2006) 969-975
31. Barrie M., Couprie C., Dufour H., Figarella-Branger D., Muracciole X., Hoang-Xuan K., et al. Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme. Ann Oncol 16 7 (2005) 1177-1184
32. Chang S.M., Prados M.D., Yung W.K., Fine H., Junck L., Greenberg H., et al. Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial. Cancer 100 8 (2004) 1712-1716
33. Prados M.D., Yung W.K., Fine H.A., Greenberg H.S., Junck L., Chang S.M., et al. Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study. Neuro-oncology 6 1 (2004) 33-37
34. Fountzilas G., Karkavelas G., Kalogera-Fountzila A., Karina M., Ignatiadis M., Koukoulis G., et al. Post-operative combined radiation and chemotherapy with temozolomide and irinotecan in patients with high-grade astrocytic tumors. A phase II study with biomarker evaluation. Anticancer Res 26 6C (2006) 4675-4686
35. Lieberman FS, Tsien C, Berkey B, Curran W, Werner-Wasik M, Smith R, et al. Phase II trial of concomitant low dose temozolomide with external beam radiation (EBRT) followed by 12 months of temozolomide and irinotecan for newly diagnosed glioblastoma (GBM): preliminary results of RTOG 04-20. J Clin Oncol 2006; 24(18S):1510.
36. Korones D.N., Benita-Weiss M., Coyle T., Bushunow P., Mechtler L., and Friedman H.S. A phase II study of temozlomide and oral VP-16 for adults with recurrent glioma-final results. J Clin Oncol 24 18S (2006) 1565
37. Tolcher A.W., Gerson S.L., Denis L., Geyer C., Hammond L.A., Patnaik A., et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 88 7 (2003 Apr 7) 1004-1011
38. Buttolo L., Giunta F., Ferrari V.D., Grisanti S., Marini G., and Mortini P. Alternative schedules of adjuvant temozolomide in glioblastoma multiforme: a 6-year experience. J Clin Oncol 24 18S (2006) 1511
39. Wong S., Rosenthal M.A., Dowling A., Jennens R., Woods A.M., Ashley D., et al. Phase II study of two-weekly temozolomide in patients with high-grade gliomas. J Clin Neurosci 13 1 (2006) 18-22
40. Vera K., Djafari L., Faivre S., Guillamo J.S., Djazouli K., Osorio M., et al. Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors. Ann Oncol 15 1 (2004) 161-171
41. Wick W., Steinbach J.P., Kuker W.M., Dichgans J., Bamberg M., and Weller M. One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. Neurology 62 11 (2004) 2113-2115
42. Khan R.B., Raizer J.J., Malkin M.G., Bazylewicz K.A., and Abrey L.E. A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro-oncology 4 1 (2002) 39-43
43. Kong D.S., Lee J.I., Kim W.S., Son M.J., Lim do H., Kim S.T., et al. A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. Oncol Rep 16 5 (2006) 1117-1121
44. Brada M., Ashley S., Dowe A., Gonsalves A., Huchet A., Pesce G., et al. Neoadjuvant phase II multicentre study of new agents in patients with malignant glioma after minimal surgery. Report of a cohort of 187 patients treated with temozolomide. Ann Oncol 16 6 (2005) 942-949
45. Soffietti R., Ruda R., Guarneri D., Laguzzi E., and Trevisan E. Recurrent/progressive oligodendroglial tumors: a phase II study with temozolomide as first line chemotherapy. J Clin Oncol 24 18S (2006) 1561
46. Soffietti R., Costanza A., Laguzzi E., Trevisan E., and Ruda R. Temozolomide in rare brain tumors of the adult: a prospective study. J Clin Oncol 23 16S (2005) 1574
47. Durando X., Thivat E., Roche H., Bay J.O., Lemaire J.J., Verrelle P., et al. Cystemustine in recurrent high grade glioma. J Neurooncol 79 1 (2006) 33-37
48. Webster M., Cairncross G., Gertler S., Perry J., Wainman N., and Eisenhauer E. Phase II trial of SarCNU in malignant glioma: unexpected pulmonary toxicity with a novel nitrosourea: a phase II trial of the national cancer institute of canada clinical trials group. Invest New Drugs 23 6 (2005) 591-596
49. Imbesi F., Marchioni E., Benericetti E., Zappoli F., Galli A., Corato M., et al. A randomized phase III study: comparison between intravenous and intraarterial ACNU administration in newly diagnosed primary glioblastomas. Anticancer Res 26 1B (2006) 553-558
50. Gwak H.S., Youn S.M., Kwon A.H., Lee S.H., Kim J.H., and Rhee C.H. ACNU-cisplatin continuous infusion chemotherapy as salvage therapy for recurrent glioblastomas: phase II study. J Neurooncol 75 2 (2005) 173-180
51. Aoki T., Takahashi J.A., Ueba T., Oya N., Hiraoka M., Matsui K., et al. Phase II study of nimustine, carboplatin, vincristine, and interferon-beta with radiotherapy for glioblastoma multiforme: experience of the Kyoto Neuro-Oncology Group. J Neurosurg 105 3 (2006) 385-391
52. Rao R.D., Krishnan S., Fitch T.R., Schomberg P.J., Dinapoli R.P., Nordstrom K., et al. Phase II trial of carmustine, cisplatin, and oral etoposide chemotherapy before radiotherapy for grade 3 astrocytoma (anaplastic astrocytoma): results of North Central Cancer Treatment Group trial 98-72-51. Int J Radiat Oncol Biol Phys 61 2 (2005) 380-386
53. Cairncross G., Berkey B., Shaw E., Jenkins R., Scheithauer B., Brachman D., et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24 18 (2006) 2707-2714
54. van den Bent M.J., Carpentier A.F., Brandes A.A., Sanson M., Taphoorn M.J., Bernsen H.J., et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24 18 (2006) 2715-2722
55. Pipas J.M., Meyer L.P., Rhodes C.H., Cromwell L.D., McDonnell C.E., Kingman L.S., et al. A Phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma. J Neurooncol 71 3 (2005) 301-305
56. Hare C.B., Elion G.B., Houghton P.J., Houghton J.A., Keir S., Marcelli S.L., et al. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharm 39 3 (1997) 187-191
57. Prados M.D., Lamborn K., Yung W.K., Jaeckle K., Robins H.I., Mehta M., et al. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro-oncology 8 2 (2006) 189-193
58. Farray D., Ahluwalia M.S., Snyder J., Barnett G.H., Cohen B.H., Suh J.H., et al. Pre-irradiation 9-amino [20s] camptothecin (9-AC) in patients with newly diagnosed glioblastoma multiforme. Invest New Drugs 24 3 (2006) 177-180
59. Reardon D.A., Quinn J.A., Vredenburgh J., Rich J.N., Gururangan S., Badruddoja M., et al. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer 103 2 (2005) 329-338
60. Feun L.G., Marini A., Landy H., Markoe A., Heros D., Robles C., et al. Clinical trial of CPT-11 and VM-26/VP-16 for patients with recurrent malignant brain tumors. J Neurooncol (2006)
61. Scopece L., Franceschi E., Cavallo G., Paioli A., Paioli G., Conforti R., et al. Carboplatin and etoposide (CE) chemotherapy in patients with recurrent or progressive oligodendroglial tumors. J Neurooncol 79 3 (2006) 299-305
62. Galanis E., Buckner J.C., Maurer M.J., Reid J.M., Kuffel M.J., Ames M.M., et al. Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: a North Central Cancer Treatment Group trial. Invest New Drugs 23 5 (2005) 495-503
63. Abrey L.E., Childs B.H., Paleologos N., Kaminer L., Rosenfeld S., Salzman D., et al. High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up. Neuro-oncology 8 2 (2006) 183-188
64. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 3 (1996) 353-364
65. Fischer I., Gagner J.P., Law M., Newcomb E.W., and Zagzag D. Angiogenesis in gliomas: biology and molecular pathophysiology. Brain Pathol (Zurich, Switzerland) 15 4 (2005) 297-310
66. Plate K.H., Breier G., Weich H.A., and Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359 6398 (1992) 845-848
67. Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. In: World Federation of Neuro-Oncology Meeting. 2005(May):91.
68. Gonzalez J., Kumar A.J., Conrad C.A., and Levin V.A. Effect of bevacizumab on radiation necrosis of the brain. Int J Rad Oncol Biol Phys 67 2 (2007) 323-326
69. Batchelor T.T., Sorensen A.G., di Tomaso E., Zhang W.T., Duda D.G., Cohen K.S., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11 1 (2007) 83-95
70. Ashby L., Troester M., and Shapiro W. Central nervous system tumors. Update Cancer Therapeut (2006) 475-513
71. Puduvalli V.K., Giglio P., Groves M., Hess K., Gilbert M., Mahankali S., et al. Phase II study of the combination of thalidomide and irinotecan in patients with recurrent anaplastic gliomas not on enzyme inducing anticonvulsants. J Clin Oncol 24 18S (2006) 1564
72. Leahy K.M., Ornberg R.L., Wang Y., Zweifel B.S., Koki A.T., and Masferrer J.L. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 62 3 (2002) 625-631
73. Castilla E.A., Prayson R.A., Kanner A.A., Rybicki L.A., Tubbs R.R., Vogelbaum M.A., et al. Cyclooxygenase-2 in oligodendroglial neoplasms. Cancer 98 7 (2003) 1465-1472
74. Tuettenberg J., Grobholz R., Korn T., Wenz F., Erber R., and Vajkoczy P. Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme. J Cancer Res Clin Oncol 131 1 (2005) 31-40
75. Brem S., Grossman S.A., Carson K.A., New P., Phuphanich S., Alavi J.B., et al. Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma. Neuro-oncology 7 3 (2005) 246-253
76. Groves M.D., Puduvalli V.K., Conrad C.A., Gilbert M.R., Yung W.K., Jaeckle K., et al. Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status. J Neurooncol 80 1 (2006) 83-90
77. Senger D.R., Ledbetter S.R., Claffey K.P., Papadopoulos-Sergiou A., Peruzzi C.A., and Detmar M. Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. Am J Pathol 149 1 (1996) 293-305
78. Tonn J.C., Wunderlich S., Kerkau S., Klein C.E., and Roosen K. Invasive behaviour of human gliomas is mediated by interindividually different integrin patterns. Anticancer Res 18 4A (1998) 2599-2605
79. Gladson C.L. Expression of integrin alpha v beta 3 in small blood vessels of glioblastoma tumors. J Neuropathol Exp Neurol 55 11 (1996) 1143-1149
80. Bello L., Francolini M., Marthyn P., Zhang J., Carroll R.S., Nikas D.C., et al. Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. Neurosurgery 49 2 (2001) 380-389 [discussion 90]
81. Taga T., Suzuki A., Gonzalez-Gomez I., Gilles F.H., Stins M., Shimada H., et al. alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Int J Cancer 98 5 (2002) 690-697
82. Yamada S., Bu X.Y., Khankaldyyan V., Gonzales-Gomez I., McComb J.G., and Laug W.E. Effect of the angiogenesis inhibitor Cilengitide (EMD 121974) on glioblastoma growth in nude mice. Neurosurgery 59 6 (2006) 1304-1312 [discussion 12]
83. Nabors L.B., Mikkelsen T., Rosenfeld S.S., Hochberg F., Akella N.S., Fisher J.D., et al. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 25 13 (2007) 1651-1657
84. Chang S.M., Lamborn K., Wen P., DeAngelis L., Fink K., Lieberman F., et al. Phase II study of POLY-ICLC in recurrent anaplastic glioma-a North American Brain Tumor Consortium study. J Clin Oncol 24 18S (2006) 1550
85. Reardon D.A., and Wen P.Y. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Oncologist 11 2 (2006) 152-164
86. Hau P., Stockhammer M., Kunst M., Mahapatra A., Sastry K.V., Parfenov V.E., et al. Results of G004, a phase IIb actively controlled clinical trial with the TGF-b2 targeted compound AP 12009 for recurrent anaplastic astrocytoma. J Clin Oncol 24 18S (2006) 1566
87. Oshiro S., Tsugu H., Komatsu F., Ohnishi H., Ueno Y., Sakamoto S., et al. Evaluation of intratumoral administration of tumor necrosis factor-alpha in patients with malignant glioma. Anticancer Res 26 6A (2006) 4027-4032
88. Groves M., Puduvalli V.K., Gilbert M., Conrad C., Hsu S., Colman H., et al. A phase II study of temozolomide plus pegylated interferon alfa-2b for recurrent anaplastic glioma and glioblastoma multiforme. J Clin Oncol 23 16S (2005) 1519
89. Colman H., Berkey B.A., Maor M.H., Groves M.D., Schultz C.J., Vermeulen S., et al. Phase II Radiation Therapy Oncology Group trial of conventional radiation therapy followed by treatment with recombinant interferon-beta for supratentorial glioblastoma: results of RTOG 9710. Int J Radiat Oncol Biol Phys 66 3 (2006) 818-824
90. Yamanaka R., Homma J., Yajima N., Tsuchiya N., Sano M., Kobayashi T., et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res 11 11 (2005) 4160-4167
91. Yamanaka R., Yajima N., Mine T., Yamada T., Shigemor M., and Ito K. Immunological evaluation of personalized peptide vaccination for patients with malignant glioma: the results of a clinical phase I trial. J Clin Oncol 24 18S (2006) 1524
92. Freeman A.I., Zakay-Rones Z., Gomori J.M., Linetsky E., Rasooly L., Greenbaum E., et al. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther 13 1 (2006) 221-228
93. Forsyth P., Roldan G., George D., Wallace C., Morris D., Cairncross G., et al. A phase I trial of intratumoral (i.t.) administration of reovirus in patients with histologically confirmed recurrent malignant gliomas (MGs). J Clin Oncol 24 18S (2006) 1563
94. Benjamin R., Capparella J., and Brown A. Classification of glioblastoma multiforme in adults by molecular genetics. Cancer J (Sudbury, Mass.) 9 2 (2003) 82-90
95. Mellinghoff I.K., Wang M.Y., Vivanco I., Haas-Kogan D.A., Zhu S., Dia E.Q., et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. New Engl J Med 353 19 (2005) 2012-2024
96. Haas-Kogan D.A., Prados M.D., Tihan T., Eberhard D.A., Jelluma N., Arvold N.D., et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 97 12 (2005) 880-887
97. Prados M.D., Lamborn K.R., Chang S., Burton E., Butowski N., Malec M., et al. Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro-oncology 8 1 (2006) 67-78
98. Vogelbaum M.A., Peereboom D.M., Stevens G., Barnett G., and Brewer C. Phase II trial of the EGFR tyrosine kinase inhibitor erlotinib for single agent therapy of recurrent Glioblastoma Multiforme: interim results. J Clin Oncol 22 14S (2004) 1558
99. Raizer JJ, Abrey LE, Wen P, Cloughesy T, et al. A phase II trial of erlotinib (OSI-774) in patients with recurrent malignnt gliomas not on EIAEDs. J Clin Oncol 2004;22(14S):1502.
100. Cloughesy T., Yung A., Vredenburgh J., Aldape K., Eberhard D.A., Prados M., et al. Phase II study of erlotinib in recurrent GBM: molecular predictors of outcome. J Clin Oncol 23 16S (2005) 1507
101. Ramos T.C., Figueredo J., Catala M., Gonzalez S., Selva J.C., Cruz T.M., et al. Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial. Cancer Biol Ther 5 4 (2006) 375-379
102. Belda-Iniesta C., Carpeno Jde C., Saenz E.C., Gutierrez M., Perona R., and Baron M.G. Long term responses with cetuximab therapy in glioblastoma multiforme. Cancer Biol Ther 5 8 (2006) 912-914
103. Combs S.E., Heeger S., Haselmann R., Edler L., Debus J., and Schulz-Ertner D. Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)-phase I/II trial: study protocol. BMC Cancer 6 (2006) 133
104. Guha A., Dashner K., Black P.M., Wagner J.A., and Stiles C.D. Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop. Int J Cancer 60 2 (1995) 168-173
105. Buchdunger E., Cioffi C.L., Law N., Stover D., Ohno-Jones S., Druker B.J., et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharm Exp Ther 295 1 (2000) 139-145
106. Wen P.Y., Yung W.K., Lamborn K.R., Dahia P.L., Wang Y., Peng B., et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 12 16 (2006) 4899-4907
107. Marosi C., Vedadinejad M., Haberler C., Hainfellner J.A., Dieckmann K., Rossler K., et al. Imatinib mesylate in the treatment of patients with recurrent high grade gliomas expressing PDGF-R. J Clin Oncol 24 18S (2006) 1526
108. Dresemann G. Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Ann Oncol 16 10 (2005) 1702-1708
109. Reardon D.A., Egorin M.J., Quinn J.A., Rich J.N., Gururangan S., Vredenburgh J.J., et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol 23 36 (2005) 9359-9368
110. Desjardins A., Reardon D.A., Quinn J.A., Rich J.N., Vredenburgh J., Sathornsumetee S., et al. Phase II trial of imatinib mesylate and hydroxyurea for grade III malignant gliomas. J Clin Oncol 24 18S (2006) 1573
111. Friedman A.H., Quinn J.A., Rich J.N., Vredenburgh J., Desjardins A., Sathornsumetee S., et al. Imatinib Mesylate (Gleevec) plus hydroxyurea is an effective regimen in the treatment of recurrent malignant glioma. Phase 2 study results. J Clin Oncol 23 16S (2005) 1515
112. Cloughesy T.F., Wen P.Y., Robins H.I., Chang S.M., Groves M.D., Fink K.L., et al. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol 24 22 (2006) 3651-3656
113. Gilbert M., Gaupp P., Liu V., Conrad C., Colman H., Groves M., et al. A phase I study of temozolomide (TMZ) and the farnesyltransferase inhibitor (FTI), lonafarnib (Sarazar, SCH66336) in recurrent glioblastoma. J Clin Oncol 24 18S (2006) 1556
114. Wang S.I., Puc J., Li J., Bruce J.N., Cairns P., Sidransky D., et al. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res 57 19 (1997) 4183-4186
115. Wiencke J.K., Zheng S., Jelluma N., Tihan T., Vandenberg S., Tamguney T., et al. Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma. Neuro Oncol 9 3 (2007) 271-279
116. Chang S.M., Wen P., Cloughesy T., Greenberg H., Schiff D., Conrad C., et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 23 4 (2005) 357-361
117. Galanis E., Buckner J.C., Maurer M.J., Kreisberg J.I., Ballman K., Boni J., et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 23 23 (2005) 5294-5304
118. Galanis E., Buckner J., Maurer M.J., Hidalgo M., Kreisberg J.I., Peralba J.M., et al. N997B: Phase II Trial of CCI-779 in Recurrent Glioblastoma Multiforme (GBM): updated results and correlative laboratory analysis. J Clin Oncol 23 16S (2005) 1505
119. Nguyen T.D., Lassman A.B., Lis E., Rosen N., Shaffer D.R., Scher H.I., et al. A pilot study to assess the tolerability and efficacy of RAD-001 (everolimus) with gefitinib in patients with recurrent glioblastoma multiforme (GBM). J Clin Oncol 24 18S (2006) 1507
120. Baltuch G.H., Dooley N.P., Villemure J.G., and Yong V.W. Protein kinase C and growth regulation of malignant gliomas. Can J Neurol Sci 22 4 (1995) 264-271
121. Robins H.I., Won M., Seiferheld W.F., Schultz C.J., Choucair A.K., Brachman D.G., et al. Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-0021. Neuro-oncology 8 1 (2006) 47-52
122. Tang P., Roldan G., Brasher P.M., Fulton D., Roa W., Murtha A., et al. A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma. J Neurooncol 78 3 (2006) 311-316
123. Diaz R., Jorda M.V., Reynes G., Aparicio J., Segura A., Amador R., et al. Neoadjuvant cisplatin and etoposide, with or without tamoxifen, prior to radiotherapy in high-grade gliomas: a single-center experience. Anti-cancer Drugs 16 3 (2005) 323-329
124. Fine H., Kim L., Royce C., Draper D., Haggarty I., Ellinzano H., et al. Results form phase II trial of Enzastaurin (LY317615) in patients with recurrent high grade gliomas. J Clin Oncol 23 16S (2005) 1504
125. Keyes K.A., Mann L., Sherman M., Galbreath E., Schirtzinger L., Ballard D., et al. LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice. Cancer Chemother Pharmacol 53 2 (2004) 133-140
126. Grossman S.A., Alavi J.B., Supko J.G., Carson K.A., Priet R., Dorr F.A., et al. Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas. Neuro-oncology 7 1 (2005) 32-40
127. Yin D., Zhou H., Kumagai T., Liu G., Ong J.M., Black K.L., et al. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene 24 3 (2005) 344-354
128. Robe P.A., Bentires-Alj M., Bonif M., Rogister B., Deprez M., Haddada H., et al. In vitro and in vivo activity of the nuclear factor-kappaB inhibitor sulfasalazine in human glioblastomas. Clin Cancer Res 10 16 (2004) 5595-5603
129. Robe P.A., Martin D., Albert A., Deprez M., Chariot A., and Bours V. A phase 1-2, prospective, double blind, randomized study of the safety and efficacy of Sulfasalazine for the treatment of progressing malignant gliomas: study protocol of [ISRCTN45828668]. BMC Cancer 6 (2006) 29
130. Costa S.L., Paillaud E., Fages C., Rochette-Egly C., Plassat J.L., Jouault H., et al. Effects of a novel synthetic retinoid on malignant glioma in vitro: inhibition of cell proliferation, induction of apoptosis and differentiation. Eur J Cancer 37 4 (2001) 520-530
131. Bouterfa H., Picht T., Kess D., Herbold C., Noll E., Black P.M., et al. Retinoids inhibit human glioma cell proliferation and migration in primary cell cultures but not in established cell lines. Neurosurgery 46 2 (2000) 419-430
132. Butowski N., Prados M.D., Lamborn K.R., Larson D.A., Sneed P.K., Wara W.M., et al. A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma. Int J Radiat Oncol Biol Phys 61 5 (2005) 1454-1459
133. Doherty L., Gigas D.C., Kesari S., Drappatz J., Kim R., Zimmerman J., et al. Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology 67 1 (2006) 156-158
134. Westphal M., Ram Z., Riddle V., Hilt D., and Bortey E. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochirurgica 148 3 (2006) 269-275 [discussion 75]
135. Menei P., Capelle L., Guyotat J., Fuentes S., Assaker R., Bataille B., et al. Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of malignant glioma: a randomized phase II trial. Neurosurgery 56 2 (2005) 242-248 [discussion 8]
136. Reardon D.A., Akabani G., Coleman R.E., Friedman A.H., Friedman H.S., Herndon II J.E., et al. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol 24 1 (2006) 115-122
137. Reardon D.A., Akabani G., Coleman R.E., Friedman A.H., Friedman H.S., Herndon II J.E., et al. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 20 5 (2002) 1389-1397
138. Gabayan A.J., Green S.B., Sanan A., Jenrette J., Schultz C., Papagikos M., et al. GliaSite brachytherapy for treatment of recurrent malignant gliomas: a retrospective multi-institutional analysis. Neurosurgery 58 4 (2006) 701-709 [discussion 9]
139. Welsh J., Sanan A., Gabayan A.J., Green S.B., Lustig R., Burri S., et al. GLIASite brachytherapy boost as part of initial treatment of glioblastoma multiforme: a retrospective multi-institutional pilot study. Int J Radiat Oncol Biol Phys 68 (2007) 159-165
140. Chan T.A., Weingart J.D., Parisi M., Hughes M.A., Olivi A., Borzillary S., et al. Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy. Int J Radiat Oncol Biol Phys 62 4 (2005) 1133-1139
141. von Eckardstein K.L., Reszka R., and Kiwit J.C. Intracavitary chemotherapy (paclitaxel/carboplatin liquid crystalline cubic phases) for recurrent glioblastoma-clinical observations. J Neurooncol 74 3 (2005) 305-309
142. Mamelak A.N., Rosenfeld S., Bucholz R., Raubitschek A., Nabors L.B., Fiveash J.B., et al. Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma. J Clin Oncol 24 22 (2006) 3644-3650
143. Weaver M., and Laske D.W. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol 65 1 (2003) 3-13
144. Hau P, Stockhammer G, Kunst M, Mahapatra A, Sastry KV, Parfenov VE, et al. Results of G004, a phase IIb actively controlled clinical trial with the TGF-b2 targeted compound AP 12009 for recurrent anaplastic astrocytoma. J Clin Oncol 2006;24(18S):1566.
145. Hau P, Kunst M, Pichler J, Parfenov V, Sastry K, et al. Targeted downregulation of TGF-beta2 as immunotherapy for high-grade glioma: a phase IIb study. J Clin Oncol 2005;23(16S):1537.
146. Patel S.J., Shapiro W.R., Laske D.W., Jensen R.L., Asher A.L., Wessels B.W., et al. Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: initial experience in 51 patients. Neurosurgery 56 6 (2005) 1243-1252 [discussion 52-3]
147. Kunwar S., Prados M.D., Chang S.M., Berger M.S., Lang F.F., Piepmeier J.M., et al. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol 25 7 (2007) 837-844
148. Kunwar S., Chang S.M., Prados M.D., Berger M.S., Sampson J.H., Croteau D., et al. Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies. Neurosurg Focus 20 4 (2006) E15
149. Doolittle N.D., Abrey L.E., Bleyer W.A., Brem S., Davis T.P., Dore-Duffy P., et al. New frontiers in translational research in neuro-oncology and the blood-brain barrier: report of the tenth annual Blood-Brain Barrier Disruption Consortium Meeting. Clin Cancer Res 11 2 Pt 1 (2005) 421-428
150. Hall W.A., Doolittle N.D., Daman M., Bruns P.K., Muldoon L., Fortin D., et al. Osmotic blood-brain barrier disruption chemotherapy for diffuse pontine gliomas. J Neurooncol 77 3 (2006) 279-284
151. Fortin D., Desjardins A., Benko A., Niyonsega T., and Boudrias M. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience. Cancer 103 12 (2005) 2606-2615
152. Kochii M., Kitamura I., Goto T., Nishi T., Takeshima H., Saito Y., et al. Randomized comparison of intra-arterial versus intravenous infusion of ACNU for newly diagnosed patients with glioblastoma. J Neurooncol 49 1 (2000) 63-70
153. Newton H.B., Figg G.M., Slone H.W., and Bourekas E. Incidence of infusion plan alterations after angiography in patients undergoing intra-arterial chemotherapy for brain tumors. J Neurooncol 78 2 (2006) 157-160
154. Ochiai H., Campbell S.A., Archer G.E., Chewning T.A., Dragunsky E., Ivanov A., et al. Targeted therapy for glioblastoma multiforme neoplastic meningitis with intrathecal delivery of an oncolytic recombinant poliovirus. Clin Cancer Res 12 4 (2006) 1349-1354
155. Kneifel S., Cordier D., Good S., Ionescu M.C., Ghaffari A., Hofer S., et al. Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance p. Clin Cancer Res 12 12 (2006) 3843-3850
156. Brown P.D., Ballman K.V., Rummans T.A., Maurer M.J., Sloan J.A., Boeve B.F., et al. Prospective study of quality of life in adults with newly diagnosed high-grade gliomas. J Neurooncol 76 3 (2006) 283-291
157. Shaw E.G., Rosdhal R., D'Agostino Jr. R.B., Lovato J., Naughton M.J., Robbins M.E., et al. Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. J Clin Oncol 24 9 (2006) 1415-1420
158. Butler C, Atkins F, Griffin L, McMullen M, Naughton R, Stieber S. A Phase III, double blind, placebo-controlled prospective randomized clinical trial of effect of d-threo-methylphenidate HCl (d-MPH) on quality of life in brain tumor patients receiving radiation therapy. I. J Radiat Oncol 2005;63(2, Supplement).
159. Bruera E., Valero V., Driver L., Shen L., Willey J., Zhang T., et al. Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol 24 13 (2006) 2073-2078
160. Kaleita T.A., Graham W.D., Steh C.A., Nghiemphu B., Ford Jm P., Lai A., Peak S., and Cloughesy T.F. Pilot study of modafinil for treatment of neurobehavioral dysfunction and fatigue in adult patients with brain tumors. J Clin Oncol 24 18S (2006) 1503
161. Villalona-Calero M.A., Eckardt J., Burris H., Kraynak M., Fields-Jones S., Bazan C., et al. A phase I trial of human corticotropin-releasing factor (hCRF) in patients with peritumoral brain edema. Ann Oncol 9 1 (1998) 71-77
162. Stege E.M., Kros J.M., de Bruin H.G., Enting R.H., van Heuvel I., Looijenga L.H., et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer 103 4 (2005) 802-809
163. Kouwenhoven M.C., Kros J.M., French P.J., Biemond-ter Stege E.M., Graveland W.J., Taphoorn M.J., et al. 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. Eur J Cancer 42 15 (2006) 2499-2503
164. Jenkins R.B., Blair H., Ballman K.V., Giannini C., Arusell R.M., Law M., et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66 20 (2006) 9852-9861
165. Brandes A.A., Tosoni A., Cavallo G., Reni M., Franceschi E., Bonaldi L., et al. Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. J Clin Oncol 24 29 (2006) 4746-4753
166. Wong E.T., Hess K.R., Gleason M.J., Jaeckle K.A., Kyritsis A.P., Prados M.D., et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17 8 (1999) 2572-2578
167. Mirimanoff R.O., Gorlia T., Mason W., Van den Bent M.J., Kortmann R.D., Fisher B., et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 24 16 (2006) 2563-2569
168. Kummar S., Kinders R., Rubinstein L., Parchment R.E., Murgo A.J., Collins J., et al. Compressing drug development timelines in oncology using phase '0' trials. Nat Rev 7 2 (2007) 131-139
169. Zimm S., Wampler G.L., Stablein D., Hazra T., and Young H.F. Intracerebral metastases in solid-tumor patients: natural history and results of treatment. Cancer 48 2 (1981) 384-394
170. Tsao M.N., Lloyd N., Wong R., Chow E., Rakovitch E., and Laperriere N. Whole brain radiotherapy for the treatment of multiple brain metastases. Cochrane Database Syst Rev (Online) 3 (2006) CD003869
171. Roos D.E., Wirth A., Burmeister B.H., Spry N.A., Drummond K.J., Beresford J.A., et al. Whole brain irradiation following surgery or radiosurgery for solitary brain metastases: mature results of a prematurely closed randomized Trans-Tasman Radiation Oncology Group trial (TROG 98.05). Radiother Oncol 80 3 (2006) 318-322
172. Aoyama H., Shirato H., Tago M., Nakagawa K., Toyoda T., Hatano K., et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs. stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 295 21 (2006) 2483-2491
173. Manon R., O'Neill A., Knisely J., Werner-Wasik M., Lazarus H.M., Wagner H., et al. Phase II trial of radiosurgery for one to three newly diagnosed brain metastases from renal cell carcinoma, melanoma, and sarcoma: an Eastern Cooperative Oncology Group study (E 6397). J Clin Oncol 23 34 (2005) 8870-8876
174. Andrews D.W., Scott C.B., Sperduto P.W., Flanders A.E., Gaspar L.E., Schell M.C., et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363 9422 (2004) 1665-1672
175. Jawahar A., Shaya M., Campbell P., Ampil F., Willis B.K., Smith D., et al. Role of stereotactic radiosurgery as a primary treatment option in the management of newly diagnosed multiple (3-6) intracranial metastases. Surg Neurol 64 3 (2005) 207-212
176. Koc M., McGregor J., Grecula J., Bauer C.J., Gupta N., and Gahbauer R.A. Gamma knife radiosurgery for intracranial metastatic melanoma: an analysis of survival and prognostic factors. J Neurooncol 71 3 (2005) 307-313
177. Goyal S., Prasad D., Harrell Jr. F., Matsumoto J., Rich T., and Steiner L. Gamma knife surgery for the treatment of intracranial metastases from breast cancer. J Neurosurg 103 2 (2005) 218-223
178. Sheehan J., Kondziolka D., Flickinger J., and Lunsford L.D. Radiosurgery for patients with recurrent small cell lung carcinoma metastatic to the brain: outcomes and prognostic factors. J Neurosurg 102 Suppl. (2005) 247-254
179. Pan H.C., Sheehan J., Stroila M., Steiner M., and Steiner L. Gamma knife surgery for brain metastases from lung cancer. J Neurosurg 102 Suppl. (2005) 128-133
180. Gerosa M., Nicolato A., Foroni R., Tomazzoli L., and Bricolo A. Analysis of long-term outcomes and prognostic factors in patients with non-small cell lung cancer brain metastases treated by gamma knife radiosurgery. J Neurosurg 102 Suppl. (2005) 75-80
181. Shuto T., Inomori S., Fujino H., and Nagano H. Gamma knife surgery for metastatic brain tumors from renal cell carcinoma. J Neurosurg 105 4 (2006) 555-560
182. Yen C.P., Sheehan J., Patterson G., and Steiner L. Gamma knife surgery for metastatic brainstem tumors. J Neurosurg 105 2 (2006) 213-219
183. Fuentes S., Delsanti C., Metellus P., Peragut J.C., Grisoli F., and Regis J. Brainstem metastases: management using gamma knife radiosurgery. Neurosurgery 58 1 (2006) 37-42 [discussion 37-42]
184. Nam T.K., Lee J.I., Jung Y.J., Im Y.S., An H.Y., Nam D.H., et al. Gamma knife surgery for brain metastases in patients harboring four or more lesions: survival and prognostic factors. J Neurosurg 102 Suppl. (2005) 147-150
185. Kamath R., Ryken T.C., Meeks S.L., Pennington E.C., Ritchie J., and Buatti J.M. Initial clinical experience with frameless radiosurgery for patients with intracranial metastases. Int J Radiat Oncol Biol Phys 61 5 (2005) 1467-1472
186. Curry Jr. W.T., Cosgrove G.R., Hochberg F.H., Loeffler J., and Zervas N.T. Stereotactic interstitial radiosurgery for cerebral metastases. J Neurosurg 103 4 (2005) 630-635
187. Aoki M., Abe Y., Hatayama Y., Kondo H., and Basaki K. Clinical outcome of hypofractionated conventional conformation radiotherapy for patients with single and no more than three metastatic brain tumors, with noninvasive fixation of the skull without whole brain irradiation. Int J Radiat Oncol Biol Phys 64 2 (2006) 414-418
188. Narayana A., Chang J., Yenice K., Chan K., Lymberis S., Brennan C., et al. Hypofractionated stereotactic radiotherapy using intensity-modulated radiotherapy in patients with one or two brain metastases. Stereotactic Funct Neurosurg 85 2-3 (2007) 82-87
189. Ernst-Stecken A., Ganslandt O., Lambrecht U., Sauer R., and Grabenbauer G. Phase II trial of hypofractionated stereotactic radiotherapy for brain metastases: results and toxicity. Radiother Oncol 81 1 (2006) 18-24
190. Lindvall P., Bergstrom P., Lofroth P.O., Henriksson R., and Bergenheim A.T. Hypofractionated conformal stereotactic radiotherapy alone or in combination with whole-brain radiotherapy in patients with cerebral metastases. Int J Radiat Oncol Biol Phys 61 5 (2005) 1460-1466
191. Auperin A., Arriagada R., Pignon J.P., Le Pechoux C., Gregor A., Stephens R.J., et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. New Engl J Med 341 7 (1999) 476-484
192. Meert A.P., Paesmans M., Berghmans T., Martin B., Mascaux C., Vallot F., et al. Prophylactic cranial irradiation in small cell lung cancer: a systematic review of the literature with meta-analysis. BMC Cancer 1 (2001) 5
193. Cao K.J., Huang H.Y., Tu M.C., and Pan G.Y. Long-term results of prophylactic cranial irradiation for limited-stage small-cell lung cancer in complete remission. Chin Med J 118 15 (2005) 1258-1262
194. Rogers L.R., Rock J.P., Sills A.K., Vogelbaum M.A., Suh J.H., Ellis T.L., et al. Results of a phase II trial of the GliaSite radiation therapy system for the treatment of newly diagnosed, resected single brain metastases. J Neurosurg 105 3 (2006) 375-384
195. Hofmann M., Kiecker F., Wurm R., Schlenger L., Budach V., Sterry W., et al. Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases. J Neurooncol 76 1 (2006) 59-64
196. Verger E., Gil M., Yaya R., Vinolas N., Villa S., Pujol T., et al. Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial. Int J Radiat Oncol Biol Phys 61 1 (2005) 185-191
197. Dawood S, Navaratnam S, Milhalcioiu C. Phase II study of concurrent temozolomide and whole brain radiation therapy in patients with brain metastasis. J Clin Oncol 2006;24(18S (June 20 Supplement)):1540.
198. Wagenius G., Brodin O., Nyman J., Greim G., Hillerdal G., Riska H., et al. Radiotherapy vs. temozolomide in the treatment of patients with lung cancer and brain metastases: a nordic randomized phase II study. J Clin Oncol 24 18S (2006) 7136
199. Kocher M., Eich H.T., Semrau R., Guner S.A., and Muller R.P. Phase I/II trial of simultaneous whole-brain irradiation and dose-escalating topotecan for brain metastases. Strahlenther Onkol 181 1 (2005) 20-25
200. Suh J.H., Stea B., Nabid A., Kresl J.J., Fortin A., Mercier J.P., et al. Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases. J Clin Oncol 24 1 (2006) 106-114
201. Mehta MP, Gervais R, Chabot P, Shapiro WR, Patchell RA, Glantz MJ, et al. Renschler MF. Motexafin gadolinium (MGd) combined with promt whole brain radiation therapy (RT) prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: Results of a phase III trial. abstract #7014, ASCO Annual Meeting 2006.
202. Mehta M.P., Rodrigus P., Terhaard C.H., Rao A., Suh J., Roa W., et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 21 13 (2003) 2529-2536
203. Cerchietti L.C., Bonomi M.R., Navigante A.H., Castro M.A., Cabalar M.E., and Roth B.M. Phase I/II study of selective cyclooxygenase-2 inhibitor celecoxib as a radiation sensitizer in patients with unresectable brain metastases. J Neurooncol 71 1 (2005) 73-81
204. Patchell R.A., Tibbs P.A., Walsh J.W., Dempsey R.J., Maruyama Y., Kryscio R.J., et al. A randomized trial of surgery in the treatment of single metastases to the brain. New Engl J Med 322 8 (1990) 494-500
205. Patchell R.A., Tibbs P.A., Regine W.F., Dempsey R.J., Mohiuddin M., Kryscio R.J., et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 280 17 (1998) 1485-1489
206. Vecht C.J., Haaxma-Reiche H., Noordijk E.M., Padberg G.W., Voormolen J.H., Hoekstra F.H., et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery?. Ann Neurol 33 6 (1993) 583-590
207. Muacevic A, Wowra B, Kreth F, Tonn, J. A randomized trial of surgery and radiotherapy versus radiosurgery alone in the treatment of single metastasis to the brain. Abstract, Deutscher Krebskongress. 2006.
208. Viani G.A., Castilho M.S., Salvajoli J.V., Pellizzon A.C., Novaes P.E., Guimaraes F.S., et al. Whole brain radiotherapy for brain metastases from breast cancer: estimation of survival using two stratification systems. BMC Cancer 7 1 (2007) 53
209. Saito E.Y., Viani G.A., Ferrigno R., Nakamura R.A., Novaes P.E., Pellizzon C.A., et al. Whole brain radiation therapy in management of brain metastasis: results and prognostic factors. Radiat Oncol (London, England) 1 (2006) 20
210. Hart MG, Grant R, Walker M, Dickinson H. Surgical resection and whole brain radiation therapy versus whole brain radiation therapy alone for single brain metastases. Cochrane database of systematic reviews (Online). 2005(1):CD003292.
211. Newton H.B., Volpi C., Burkart J., Miner M.E., Gahbauer R.A., Pearl D.K., et al. Phase III randomized multicenter tiral of surgical resection, BCNU-impregnated wafers, and irradiation versus surgical resection and irradiation alone for treatment of operable, solitary brain metastasis from systemic cancer. J Clin Oncol 24 18S (2006) 11513
212. Seute T., Leffers P., Wilmink J.T., ten Velde G.P., and Twijnstra A. Response of asymptomatic brain metastases from small-cell lung cancer to systemic first-line chemotherapy. J Clin Oncol 24 13 (2006) 2079-2083
213. Giorgio C.G., Giuffrida D., Pappalardo A., Russo A., Santini D., Salice P., et al. Oral temozolomide in heavily pre-treated brain metastases from non-small cell lung cancer: phase II study. Lung Cancer (Amsterdam, Netherlands) 50 2 (2005) 247-254
214. Schadendorf D., Hauschild A., Ugurel S., Thoelke A., Egberts F., Kreissig M., et al. Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study. Ann Oncol 17 10 (2006) 1592-1597
215. Hwu W.J., Lis E., Menell J.H., Panageas K.S., Lamb L.A., Merrell J., et al. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. Cancer 103 12 (2005) 2590-2597
216. Krown S.E., Niedzwiecki D., Hwu W.J., Hodgson L., Houghton A.N., and Haluska F.G. Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). Cancer 107 8 (2006) 1883-1890
217. Christodoulou C., Bafaloukos D., Linardou H., Aravantinos G., Bamias A., Carina M., et al. Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study. J Neurooncol 71 1 (2005) 61-65
218. Cortot A.B., Geriniere L., Robinet G., Breton J.L., Corre R., Falchero L., et al. Phase II trial of temozolomide and cisplatin followed by whole brain radiotherapy in non-small-cell lung cancer patients with brain metastases: a GLOT-GFPC study. Ann Oncol 17 9 (2006) 1412-1417
219. Caraglia M., Addeo R., Costanzo R., Montella L., Faiola V., Marra M., et al. Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours. Cancer Chemother Pharmacol 57 1 (2006) 34-39
220. Lin N.U., Carey L.A., Liu M.C., Younger J., Come S.E., Bullitt E., et al. Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer. J Clin Oncol 24 18S (2006) 503
221. Popat S., Hughes S., Papadopoulos P., Wilkins A., Moore S., Priest K., et al. Recurrent responses to non-small cell lung cancer brain metastases with erlotinib. Lung Cancer (Amsterdam, Netherlands) 56 1 (2007) 135-137
222. Lai C.S., Boshoff C., Falzon M., and Lee S.M. Complete response to erlotinib treatment in brain metastases from recurrent NSCLC. Thorax 61 1 (2006) 91
223. Nishi N., Kawai S., Yonezawa T., Fujimoto K., and Masui K. Effect of gefitinib on brain metastases from non-small cell lung cancer. Neurologia medico-Chirurgica 46 10 (2006) 504-507
224. Roggero E., Busi G., Palumbo A., and Pedrazzini A. Gefitinib ('Iressa', ZD1839) is active against brain metastases in a 77-year old patient. J Neuro-Oncol 71 3 (2005) 277-280
225. Stemmler H.J., Weigert O., Krych M., Schoenberg S.O., Ostermann H., and Hiddemann W. Brain metastases in metastatic non-small cell lung cancer responding to single-agent gefitinib: a case report. Anti-cancer Drugs 16 7 (2005) 747-749
226. Sakai M., Ishikawa S., Ito H., Ozawa Y., Yamamoto T., Onizuka M., et al. Carcinomatous meningitis from non-small-cell lung cancer responding to gefitinib. Int J Clin Oncol/Japan Soc Clin Oncol 11 3 (2006) 243-245
227. Kim M.K., Lee K.H., Lee J.K., Choi J.H., and Hyun M.S. Gefitinib is also active for carcinomatous meningitis in NSCLC. Lung Cancer (Amsterdam, Netherlands) 50 2 (2005) 265-269
228. Chiu C.H., Tsai C.M., Chen Y.M., Chiang S.C., Liou J.L., and Perng R.P. Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. Lung Cancer (Amsterdam, Netherlands) 47 1 (2005) 129-138
229. Knisely J.P., Berkey B.A., Chakravarti A., Yung W.K., Curran W., Robins H.I., et al. RTOG 0118: A Phase III Study of Conventional Radiation Therapy Alone vs. Conventional Radiation Therapy Plus Thalidomide for Multiple Brain Metastases. J Clin Oncol 23 16S (2005) 1500
230. Grossman S.A., Finkelstein D.M., Ruckdeschel J.C., Trump D.L., Moynihan T., and Ettinger D.S. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol 11 3 (1993) 561-569
231. Hitchins R.N., Bell D.R., Woods R.L., and Levi J.A. A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 5 10 (1987) 1655-1662
232. Glantz M.J., LaFollette S., Jaeckle K.A., Shapiro W., Swinnen L., Rozental J.R., et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 17 10 (1999) 3110-3116
233. Glantz M.J., Jaeckle K.A., Chamberlain M.C., Phuphanich S., Recht L., Swinnen L.J., et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 5 11 (1999) 3394-3402
234. Rogers L.R., Chamberlain M., and Glantz M.J. Evidence-based review of intrathecal chemotherapy ini outcome of patients with leptomeningeal metastasis. J Clin Oncol 24 18S (2006) 1529
235. Shapiro W.R., Schmid M., Glantz M.J., and Miller J.J. A randomized phase III/IV study to determine benefit and safety of cytarabine liposome injection for treatment of neoplastic meningitis. J Clin Oncol 24 18S (2006) 1528
236. Glantz M.J., Chamberlain M., Batchelor T., Eric W., Cavalli F., and Shapiro W. Interaction between route of intra-CSF chemotherapy administration and efficacy of therapy in patients with neoplastic meningitis. J Clin Oncol 24 18S (2006) 1530
237. Chamberlain M.C., Tsao-Wei D.D., and Groshen S. Phase II trial of intracerebrospinal fluid etoposide in the treatment of neoplastic meningitis. Cancer 106 9 (2006) 2021-2027
238. Hochberg F.H., Baehring J.M., and Hochberg E.P. Primary CNS lymphoma. Nat Clin Pract 3 1 (2007) 24-35
239. Herrlinger U., Kuker W., Uhl M., Blaicher H.P., Karnath H.O., Kanz L., et al. NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. Ann Neurol 57 6 (2005) 843-847
240. Fischer L., Thiel E., Klasen H., Hans K., Jahnke K., Pees H., et al. Long term remissions in relapsed/refractory primary central nervous system lymphoma (PCNSL) after topotecan chemotherapy. J Clin Oncol 23 16S (2005) 1528
241. Kawamura T., Ishiguchi T., Shibamoto Y., Ogino H., Ishihara S., Yamada T., et al. Results of primary central nervous system lymphoma treated by radiation and chemotherapy: retrospective analysis of twelve institutions in the Tokai District of Japan, 1995-1999. Radiat Med 24 1 (2006) 9-16
242. Shibamoto Y., Ogino H., Hasegawa M., Suzuki K., Nishio M., Fujii T., et al. Results of radiation monotherapy for primary central nervous system lymphoma in the 1990s. Int J Radiat Oncol Biol Phys 62 3 (2005) 809-813
243. Shenkier T.N., Voss N., Chhanabhai M., Fairey R., Gascoyne R.D., Hoskins P., et al. The treatment of primary central nervous system lymphoma in 122 immunocompetent patients: a population-based study of successively treated cohorts from the British Colombia Cancer Agency. Cancer 103 5 (2005) 1008-1017
244. Nguyen P.L., Chakravarti A., Finkelstein D.M., Hochberg F.H., Batchelor T.T., and Loeffler J.S. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol 23 7 (2005) 1507-1513
245. Fisher B., Seiferheld W., Schultz C., DeAngelis L., Nelson D., Schold S.C., et al. Secondary analysis of Radiation Therapy Oncology Group study (RTOG) 9310: an intergroup phase II combined modality treatment of primary central nervous system lymphoma. J Neurooncol 74 2 (2005) 201-205
246. Omuro A.M., DeAngelis L.M., Yahalom J., and Abrey L.E. Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up. Neurology 64 1 (2005) 69-74
247. Illerhaus G., Marks R., Ihorst G., Guttenberger R., Ostertag C., Derigs G., et al. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol 24 24 (2006) 3865-3870
248. Colombat P., Lemevel A., Bertrand P., Delwail V., Rachieru P., Brion A., et al. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant 38 6 (2006) 417-420
249. Brevet M., Garidi R., Gruson B., Royer B., Vaida I., and Damaj G. First-line autologous stem cell transplantation in primary CNS lymphoma. Euro J Haematol 75 4 (2005) 288-292
250. Prados M., Kunwar S., Lang F.F., Ram Z., Westphal M., Barnett G., et al. Final results of Phase I/II studies of IL 13-PE38QQR administered intratumorally (IT) and/or peritumorally (PT) via convection-enhanced delivery (CED) in patients undergoing tumor resection for recurrent malignant glioma. J Clin Oncol 23 16S (2005) 1506
251. Christopoulou A., Retsas S., Kingsley D., Paddick I., and Lindquist C. Integration of gamma knife surgery in the management of cerebral metastases from melanoma. Melanoma Res 16 1 (2006) 51-57
252. Lorusso V., Galetta D., Giotta F., Rinaldi A., Romito S., Brunetti C., et al. Topotecan in the treatment of brain metastases. A phase II study of GOIM (Gruppo Oncologico dell'Italia Meridionale). Anticancer Res 26 3B (2006) 2259-2263